About
CAR T-cells have revolutionized cancer treatment through their precise targeting capabilities. While impactful, current implementations require crucial improvements to maximize safety and efficacy. At GoCART, we are tackling these challenges head-on with our proprietary AND-gate technology, and we are building it using a transparent, community-driven development model.
Key challenges of existing CAR T-Cell Therapies:
- On-Target, Off-Tumor Toxicity
CAR T-cells may attack healthy tissues expressing similar antigens, creating safety risks. - Tumor Antigen Escape
Tumors can mutate target antigens, evading immune detection. - High Cost and Complex Manufacturing
Personalized production remains expensive and difficult to scale. - Loss of Therapeutic Efficacy
T-cell exhaustion limits long-term effectiveness.
Our Technology
AND-Gate Logic (Current Focus)
Our proprietary dual-antigen verification system requires simultaneous recognition of two tumor-specific markers through synthetic receptor pairs. This significantly reduces off-target effects while maintaining anti-tumor potency.
Hypoxia Switch (Future Pipeline)
Future development: Oxygen-responsive genetic circuit activating therapeutic functions exclusively in hypoxic tumor environments.
What is DeSci?
DeSci implements token-based governance over intellectual property through legally-binding Sponsored Research Agreements (SRAs). Our framework features:
- IP ownership governed by token holders
- Transparent research accounting via smart contracts
- Community-driven resource allocation
How GoCART Uses DeSci
Token-Based Funding
We're pioneering GoCART Intellectual Property Token ($GCRT) to democratize biotech investment while aligning stakeholder incentives through transparent, blockchain-based agreements.
Open Science Collaboration
All non-sensitive research data is accessible through decentralized storage platforms, enabling global collaboration.
Our Team
Henry Erdlei
Henry conducted doctoral research in translational tumour immunology at the Max Delbrück Center for Molecular Medicine, following his medical training at Charité – Universitätsmedizin Berlin. His work focuses on bridging fundamental immunology discoveries with clinical applications for solid tumor therapies.
Araliym Myrzagaliyeva
Arailym oversees technological development with experience spanning synthetic biology and global health advocacy. As Founder of the Breast Cancer Awareness Foundation in Kazakhstan and former Product Director at NanoX, she brings unique perspective to therapeutic development.
Chase Blakeley
Chase manages project coordination, GoCART Intellectual Property Token ($GCRT) strategy, and community engagement. With 4+ years in high-tech business development at StoryBuilt and Oracle, he combines analytical rigor with operational excellence. Chase holds a B.S. in Economics from Southern Methodist University and is passionate about advancing decentralized biotech innovation.
Resources
Our Roadmap
- Q4 2025: Achieve in vitro Proof-of-Concept for our AND-gate platform.
- 2026: Complete preclinical in vivo validation and file foundational patents.
- 2027+: Prepare for GMP manufacturing and IND-enabling studies.